Skip to main content

Site notifications

RYALTRIS (Seqirus Pty Ltd)

Product name
RYALTRIS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
201 (255 working days)
Active ingredients
mometasone furoate monohydrate; olopatadine hydrochloride
Registration type
EOI
Indication

RYALTRIS (nasal spray) is now also indicated for the treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients 6 years of age and older.